Skip to content

Study · Non-randomized trial · n = 15 · 2024

4 results

Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.

Grech O, Mitchell JL, Lyons HS, Yiangou A, Thaller M, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ

Eye (London, England)11 Jan 2024Cited by 26 (Europe PMC)

PMID38212401 (opens in a new tab)PMCIDPMC11076535 (opens in a new tab)DOI10.1038/s41433-023-02908-y (opens in a new tab)PepBankPUB-38212401
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundCognitive function can be affected in conditions with raised intracranial pressure (ICP) such as idiopathic intracranial hypertension (IIH). Drugs used off label to treat raised ICP also have cognitive side effects, underscoring the unmet need for effective therapeutics which reduce ICP without worsening cognition. The Glucagon Like Peptide-1 (GLP-1) receptor agonist, exenatide, has been shown to significantly reduce ICP in IIH, therefore this study aimed to determine the effects of exenatide on cognition in IIH.MethodsThis was an exploratory study of the IIH:Pressure trial (ISTCRN 12678718). Women with IIH and telemetric ICP monitors (n = 15) were treated with exenatide (n = 7) or placebo (n = 8) for 12 weeks. Cognitive function was tested using the National Institute of Health Toolbox Cognitive Battery at baseline and 12 weeks.ResultsCognitive performance was impaired in fluid intelligence ((T-score of 50 = population mean), mean (SD) 37.20 (9.87)), attention (33.93 (7.15)) and executive function (38.07 (14.61)). After 12-weeks there was no evidence that exenatide compromised cognition (no differences between exenatide and placebo). Cognition improved in exenatide treated patients in fluid intelligence (baseline 38.4 (8.2), 12 weeks 52.9 (6.6), p = 0.0005), processing speed (baseline 43.7 (9.4), 12 weeks 58.4 (10.4), p = 0.0058) and episodic memory (baseline 49.4 (5.3), 12 weeks 62.1 (13.2), p = 0.0315).ConclusionsIn patients with raised ICP due to IIH, exenatide, a drug emerging as an ICP lowering agent, does not adversely impact cognition. This is encouraging and has potential to be relevant when considering prescribing choices to lower ICP.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialSafety outcome

    In women with idiopathic intracranial hypertension, cognition did not differ between exenatide and placebo after treatment.

    In plain wordsIn women with idiopathic intracranial hypertension, cognition did not differ between exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCognition versus placebo
    Study

    n = 15

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    After 12-weeks there was no evidence that exenatide compromised cognition (no differences between exenatide and placebo).
    1 context sentence
    Summary · context
    This was an exploratory study of the IIH:Pressure trial (ISTCRN 12678718). Women with IIH and telemetric ICP monitors (n = 15) were treated with exenatide (n = 7) or placebo (n = 8) for 12 weeks. Cognitive function was tested using the National Institute of Health Toolbox Cognitive Battery at baseline and 12 weeks.

Studies that did not test the peptide alone3

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 02HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In women with idiopathic intracranial hypertension treated with exenatide, fluid intelligence was higher at 12 weeks than at baseline, while the abstract reports no differences between exenatide and placebo.

    In plain wordsIn women with idiopathic intracranial hypertension on exenatide, fluid intelligence rose from baseline, but cognition did not differ from placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFluid intelligence
    Study

    n = 7

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    Fluid intelligence
    38.4 score
    Baseline
    Fluid intelligence
    52.9 score
    12 weeks

    Source sentences

    Summary
    Cognition improved in exenatide treated patients in fluid intelligence (baseline 38.4 (8.2), 12 weeks 52.9 (6.6), p = 0.0005), processing speed (baseline 43.7 (9.4), 12 weeks 58.4 (10.4), p = 0.0058) and episodic memory (baseline 49.4 (5.3), 12 weeks 62.1 (13.2), p = 0.0315).
    2 context sentences
    Summary · context
    After 12-weeks there was no evidence that exenatide compromised cognition (no differences between exenatide and placebo).
    Summary · context
    This was an exploratory study of the IIH:Pressure trial (ISTCRN 12678718). Women with IIH and telemetric ICP monitors (n = 15) were treated with exenatide (n = 7) or placebo (n = 8) for 12 weeks. Cognitive function was tested using the National Institute of Health Toolbox Cognitive Battery at baseline and 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 03HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In women with idiopathic intracranial hypertension treated with exenatide, processing speed was higher at 12 weeks than at baseline, while the abstract reports no differences between exenatide and placebo.

    In plain wordsIn women with idiopathic intracranial hypertension on exenatide, processing speed rose from baseline, but cognition did not differ from placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseProcessing speed
    Study

    n = 7

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    Processing speed
    43.7 score
    Baseline
    Processing speed
    58.4 score
    12 weeks

    Source sentences

    Summary
    Cognition improved in exenatide treated patients in fluid intelligence (baseline 38.4 (8.2), 12 weeks 52.9 (6.6), p = 0.0005), processing speed (baseline 43.7 (9.4), 12 weeks 58.4 (10.4), p = 0.0058) and episodic memory (baseline 49.4 (5.3), 12 weeks 62.1 (13.2), p = 0.0315).
    2 context sentences
    Summary · context
    After 12-weeks there was no evidence that exenatide compromised cognition (no differences between exenatide and placebo).
    Summary · context
    This was an exploratory study of the IIH:Pressure trial (ISTCRN 12678718). Women with IIH and telemetric ICP monitors (n = 15) were treated with exenatide (n = 7) or placebo (n = 8) for 12 weeks. Cognitive function was tested using the National Institute of Health Toolbox Cognitive Battery at baseline and 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 04HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In women with idiopathic intracranial hypertension treated with exenatide, episodic memory was higher at 12 weeks than at baseline, while the abstract reports no differences between exenatide and placebo.

    In plain wordsIn women with idiopathic intracranial hypertension on exenatide, memory of events rose from baseline, but cognition did not differ from placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEpisodic memory
    Study

    n = 7

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Cognition and memory · Nervous system and cognition

    Measurements

    Episodic memory
    49.4 score
    Baseline
    Episodic memory
    62.1 score
    12 weeks

    Source sentences

    Summary
    Cognition improved in exenatide treated patients in fluid intelligence (baseline 38.4 (8.2), 12 weeks 52.9 (6.6), p = 0.0005), processing speed (baseline 43.7 (9.4), 12 weeks 58.4 (10.4), p = 0.0058) and episodic memory (baseline 49.4 (5.3), 12 weeks 62.1 (13.2), p = 0.0315).
    2 context sentences
    Summary · context
    After 12-weeks there was no evidence that exenatide compromised cognition (no differences between exenatide and placebo).
    Summary · context
    This was an exploratory study of the IIH:Pressure trial (ISTCRN 12678718). Women with IIH and telemetric ICP monitors (n = 15) were treated with exenatide (n = 7) or placebo (n = 8) for 12 weeks. Cognitive function was tested using the National Institute of Health Toolbox Cognitive Battery at baseline and 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.